Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239950 | 0.90 | HSD11B1 (0.61) | HSD11B1HSD11B2 | |
| SCHEMBL974109 | 0.86 | HSD11B1 (1.00) | HSD11B1HSD11B2 | |
| SCHEMBL16208166 | 0.86 | HSD11B1 (0.78) | HSD11B1HSD11B2 | |
| SCHEMBL973930 | 0.86 | HSD11B1 (0.81) | HSD11B1HSD11B2 | |
| SCHEMBL973931 | 0.86 | HSD11B1 (0.81) | HSD11B1HSD11B2 | |
| SCHEMBL973452 | 0.85 | HSD11B1 (0.82) | HSD11B1HSD11B2 | |
| SCHEMBL975298 | 0.85 | HSD11B1 (0.84) | HSD11B1HSD11B2 | |
| SCHEMBL973800 | 0.84 | HSD11B1 (0.82) | HSD11B1HSD11B2 | |
| SCHEMBL974188 | 0.84 | HSD11B1 (1.00) | HSD11B1HSD11B2 | |
| SCHEMBL974690 | 0.84 | HSD11B1 (0.80) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459549-B1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-19 | — | — | EP | disclosed |
| US-8530473-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11β-hydroxysteroid dehydrogenase type 1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-8530473-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11β-hydroxysteroid dehydrogenase type 1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | disclosed |
| WO-2011012801-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CBR3, CBR1, OXGR1 | HSD11B1 1963/4885HSD11B2 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.